Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.

ABSTRACT:

Objective

Olanzapine (OLZ) is an atypical antipsychotic whose clinical efficacy is hampered by side effects including weight gain and diabetes. Recent evidence shows that OLZ alters insulin sensitivity independent of changes in body weight and composition. The present study addresses whether OLZ-induced insulin resistance is driven by its central actions.

Research design and methods

Sprague-Dawley rats received an intravenous (OLZ-IV group) or intracerebroventricular (OLZ-ICV group) infusion of OLZ or vehicle. Glucose kinetics were assessed before (basal period) and during euglycemic-hyperinsulinemic clamp studies.

Results

OLZ-IV caused a transient increase in glycemia and a higher rate of glucose appearance (R(a)) in the basal period. During the hyperinsulinemic clam

SUBMITTER: Martins PJ 

PROVIDER: S-EPMC3279549 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature